Pneumonia Testing Market to be driven by rising prevalence of pneumonia is expected to grow at a CAGR of 4.00% during the forecast period 2024 to 2032

Market Research Future (MRFR) has published a cooked research report on the “Global Pneumonia Testing Market” that contains information from 2019 to 2032. The pneumonia testing market is estimated to register a CAGR of 4.00% during the forecast period of 2024 to 2032.

Market Highlights

The global pneumonia testing market is accounted to register a CAGR of 4.00% during the forecast period and is estimated to reach USD 1.017 billion by 2032.

The market for pneumonia testing appears to have a bright future; steady expansion is anticipated over the next few years. The primary drivers propelling market expansion are the increasing prevalence of pneumonia, technological developments in diagnostics, and growing consciousness regarding the criticality of prompt diagnosis. Significant growth prospects are expected to arise from emerging economies, point-of-care testing solutions, and technology breakthroughs. Companies in the industry that are able to adjust to changing consumer preferences, fill gaps in the market, and provide dependable and effective testing solutions will be successful in this cutthroat environment.

Key Players

MRFR recognizes the following companies as the key players in the global pneumonia testing market - Bio-Rad Laboratories, Inc., Abbott, BioMérieux SA, Meridian Bioscience, Hologic Inc., Becton, Dickinson and Company, Curetis, Thermo Fisher Scientific, and Quidel Corporation.

Segment Analysis

The global pneumonia testing market has been segmented into Product Type, Technology, Method Type and End-user.

On the basis of product type, the market is segmented into Consumable and Analyzer. The analyzer segment was attributed to holding the largest market share in 2023, which is ascribed to global increases in the occurrence of pneumonia, technological breakthroughs, and the growing need for precise and quick diagnostic treatments. The market is seeing a rise in the use of analyzers because they provide quick turnaround times and enhanced diagnostic accuracy through automated and efficient testing methods.

Based on technology, the global pneumonia testing market has been segmented into Enzyme-Linked Immunosorbent Assay (ELISA), Immunofluroscence, Immunohistochemistry (IHC), Polymerase Chain Reaction (PCR), and Others. The Enzyme-Linked Immunosorbent Assay (ELISA) segment was expected to hold the largest market share in 2023. Infectious diseases like dengue, hepatitis, AIDS, neurological disorders, and cancer are predicted to be the main drivers of ELISA demand during the course of the projection period. Toxicology, immunology, drug discovery, transplantation, pharmaceuticals, infectious disorders, cancer, and protein quantification are just a few of the many additional domains it finds application in.

Based on method type, the global pneumonia testing market has been segmented into Immunodiagnostic, Molecular Diagnostic, and Point-of-Care (POC) Testing. The point-of-care (POC) testing segment was expected to hold the largest market share in 2023. The most accurate means to diagnose pneumonia at the moment is POC testing, a state-of-the-art technique. The increased usage of POC testing can be attributed to three factors: an increase in pneumonia cases, its higher efficiency, and its highly requested rapid test results.

Based on end user, the global pneumonia testing market has been segmented into Hospitals, Diagnostic Centers, and Others. The hospitals segment was expected to hold the largest market share in 2023. The market is growing because more people are being tested for pneumonia. Among adults in the US, pneumonia is one of the main causes of death and hospitalization. Pneumonia-related hospital admissions have been rising, and this trend is especially noticeable in older persons (those over 65).

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Pneumonia Testing Market Research Report

Regional Analysis

The global pneumonia testing market, based on region, has been divided into North America, Europe, Asia-Pacific, and Rest of the World. North America consists of the US and Canada. The Europe pneumonia testing market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The pneumonia testing market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World pneumonia testing market comprises the Middle East, Africa, and Latin America.

The largest market share for pneumonia testing was maintained by the North American regional sector. The primary factors propelling the growth of the pneumonia testing market in North America are the rising prevalence of chronic diseases, increases in healthcare spending, the surge in the presence of sophisticated healthcare infrastructure, the expansion of reimbursement options, and the emergence of significant market players in the area.

Moreover, the Europe market has been persistently growing over the forecast period. The rise in hospitalizations and the important government campaigns to educate the public about pneumonia testing are to blame for the growth. For instance, a study published in January 2021 by BMC found that in Europe, respiratory disorders account for 15.0% of deaths that occur in hospitals, with pneumonia ranking as the second most common cause.

Additionally, Asia Pacific is anticipated to experience the quickest growth over the forecast period because of a number of variables, including an increase in pneumonia cases, an increase in the number of elderly people, and the existence of numerous government campaigns to enhance public awareness of pneumonia. The development of new and sophisticated diagnostic technologies, together with an increase in healthcare spending, is driving the growth of the pneumonia testing market in Asia Pacific.

Furthermore, the rest of the world's pneumonia testing market is divided into the Middle East, Africa, and Latin America. As a result of growing awareness in recent years, Latin America would grow. Important businesses in the leading industry may find attractive prospects as a result of the unmet need for pneumonia testing in Mexico and Brazil. In addition, the Middle East and Africa have a smaller market share. However, growth opportunities are anticipated as a result of increased public knowledge and better government policies among the populace of developing nations in these areas.

Key Findings of the Study

• The global pneumonia testing market is expected to reach USD 1.017 billion by 2032, at a CAGR of 4.00% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market due to several factors, such as a rise in the number of elderly individuals, a rise in pneumonia cases, and the ongoing implementation of multiple government initiatives aimed at raising public awareness of the illness.


• Based on method type, the point-of-care (POC) testing segment was attributed to holding the largest market in 2023, with an approximate market share of 35%.


• Bio-Rad Laboratories, Inc., Abbott, BioMérieux SA, Meridian Bioscience, Hologic Inc., Becton, Dickinson and Company, Curetis, Thermo Fisher Scientific, and Quidel Corporation are the key market players.